Some here have alluded to there not being any announcement regarding the outcome of the TypeC meeting with the FDA until the official minutes have been received; I’m of the opinion that there’s nothing awry with announcing something along the lines of the following: In principal endpoint agreement reached between Neuren and the FDA after successful Type C meeting and following up with unofficial details of the endpoints which will be confirmed by the FDA in their official minutes to Neuren within 30 days; and hopefully this - Upon official confirmation Neuren anticipates that the P3 costing will not exceed our preliminary estimates and accordingly expects the SBB to be extended and increased by $Xm.
NEU Price at posting:
$9.86 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)